ScoreWhy is TScan Therapeutics, Inc. ?
1
The company has declared Negative results for the last 5 consecutive quarters
- NET SALES(9M) At USD 5.91 MM has Grown at -28.88%
- OPERATING CASH FLOW(Y) Lowest at USD -126.78 MM
- OPERATING PROFIT(Q) Lowest at USD -37.96 MM
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -78.35%, its profits have fallen by -34.7%
3
High Institutional Holdings at 88.25%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 2.91% over the previous quarter.
4
Below par performance in long term as well as near term
- Along with generating -78.35% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to TScan Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is TScan Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
TScan Therapeutics, Inc.
-75.72%
-0.96
92.55%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-82.89%
EBIT Growth (5y)
-369.91%
EBIT to Interest (avg)
-34.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.34%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.48
EV to EBIT
0.81
EV to EBITDA
0.83
EV to Capital Employed
26.00
EV to Sales
-25.49
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3223.30%
ROE (Latest)
-62.03%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET SALES(HY)
Higher at USD 5.25 MM
NET PROFIT(HY)
Higher at USD -71.08 MM
RAW MATERIAL COST(Y)
Fallen by -169.9% (YoY
-11What is not working for the Company
NET SALES(9M)
At USD 5.91 MM has Grown at -28.88%
OPERATING CASH FLOW(Y)
Lowest at USD -126.78 MM
OPERATING PROFIT(Q)
Lowest at USD -37.96 MM
PRE-TAX PROFIT(Q)
Lowest at USD -36.95 MM
NET PROFIT(Q)
Lowest at USD -36.95 MM
Here's what is working for TScan Therapeutics, Inc.
Net Sales
At USD 5.25 MM has Grown at 376.13%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 5.25 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -169.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for TScan Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -126.78 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Operating Profit
Lowest at USD -37.96 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -36.95 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -36.95 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
